Google
PTCT — PTC THERAPEUTICS INC (Healthcare >> Biotechnology)
PTCT FAQ
What is PTCT's P/E ratio?
PTC THERAPEUTICS INC (PTCT) currently trades at a P/E ratio of 368.62.
What is PTCT's ROE?
PTC THERAPEUTICS INC reports a Return on Equity (ROE) of 103.47%.
What is PTCT's dividend yield?
PTC THERAPEUTICS INC offers a dividend yield of 0.00%.
What is PTCT's Deepscope Quality Score?
Deepscope rates PTCT's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PTCT?
Deepscope's AI Timing Score for PTCT is 94 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PTCT belong to?
PTC THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 70.97
Price
0.33
(0.47%)
Day Change
|
|
|---|
PTCT, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
1641
|
| Magic Formula Rank by ROE |
1641
|
| Magic Formula Rank by ROIC |
1643
|
| Price | 70.97 |
| PBV / Sector |
-32.47 / 4.63
|
| Earning Per Share | -2.26 |
| PE / Sector |
368.62 / 17.43
|
| PEG or PE/Growth / Sector |
-3.69 / 0.53
|
| Average 1M Daily Value |
99.35 M
|
| Average 1W Daily Value |
74.01 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:07 |
| Symbol | PTCT |
| Name | PTC THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 82.95 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,859.54 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059
Phone: 908 222 7000
Website: https://www.ptcbio.com
Employees: 991
Sector: Healthcare >> Biotechnology
Description: PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
